Navigation Links
Essilor Cancels 700,000 Shares
Date:11/22/2007

CHARENTON-LE-PONT, France, November 22 /PRNewswire-FirstCall/ -- Essilor yesterday cancelled 700,000 shares as part of its commitment to shareholders to offset the dilutive impact of stock option and performance share plans.

At the end of 2006, Essilor's Board of Directors authorized the granting of 930,740 stock options and 576,264 performance shares to employees. These grants will potentially lead to the issuance of up to 1,507,004 new shares between 2009 and 2011, depending on Essilor's share performance. They reflect Essilor's commitment to allowing employees to share the benefits of business growth.

Essilor is also committed to protecting its shareholders' interests, by implementing share buyback programs.

In line with this policy, since the beginning of the second half the Company has bought back and canceled 400,000 convertible bonds due 2010 - reducing by 800,000 the number of shares to be issued in the event that the bonds are converted - and has canceled 700,000 shares held in treasury, in order to offset the dilutive impact of these grants.

In addition, 500,000 shares were bought back in September and a further 500,000 during the current month.

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Airwear(R), Essilor(R) and Definity(TM)brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 244 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index (ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF FP).

Investor Relations and Financial Communications

Veronique Gillet

Phone: +33(0)1-49-77-42-16

http://www.essilor.com


'/>"/>
SOURCE Essilor
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Essilors 2007 Third-Quarter Report
2. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
3. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
4. Neuralstem Shares Accepted for Trading on Amex(R)
5. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
6. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... 11 EntreMed, Inc. (Nasdaq: ENMD ... in royalty revenue from sales of Thalomid® during ... of $3.3 million. In addition, the Company ... revenue for fiscal 2009. The difference in ... will be reflected in the fourth quarter financial ...
(Date:12/11/2009)... December 2009 -- Researchers have discovered a new explanation for ... more excess copies of a certain gene, the more serious ... and it is suspected that it is the amount of ... are being published in the American Journal of Human ... group of Guy Froyen connected to VIB, a life sciences ...
(Date:12/11/2009)... December 11 Algeta ASA (OSE: ... first clinical center in the,US, the Tulane ... patients,in the phase III clinical study of ... hormone-refractory) prostate cancer,(CRPC) that has metastasized to ... The ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) ...
(Date:12/11/2009)... Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the ... Warrander to the role of Senior Vice President, ... will be responsible for the execution of the ... Thompson, President and CEO of Oncolytics. "Having reached ... 3 trial examining REOLYSIN in combination with paclitaxel ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2Amount of gene surplus determines severity of mental retardation in males 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
... Extension Builds on Existing Brand Strength and Pediatric ... ... Focus, PLYMOUTH MEETING, Pa., Aug. 18 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone ... Sunstone (Tangshan) Pharmaceutical Co., Ltd.,("Sunstone"), its wholly-owned subsidiary, has received ...
... FOUR.OB) today announced it has appointed FBI Supervising Special Agent (Ret.) Dr. ... , ... NEW YORK (Business Wire EON) August 18, 2008 -- ... Federal Bureau of Investigation. Dr. Philip Hayden has spent years involved in ...
... SHANGHAI, China, Aug. 18 /PRNewswire-FirstCall/,-- MicuRx ... next-generation antibiotics, today announced the nomination ... development candidate. MRX-I is an,antibacterial molecule ... Staphylococcus aureus (MRSA).,Simultaneously, the company expanded ...
Other Biology Technology:BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 2BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 3BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC 4 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 2 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 4MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China 2
(Date:12/15/2009)... San Diego, California, has been awarded an accreditation ... on results of a recent onsite inspection. ... this national recognition and congratulated for the "excellence ... GenWay Clinical Laboratory is one of nearly 7,000 ... Program, begun in the early 1960s, is recognized ...
(Date:12/15/2009)... researchers found the fossil remains of a whale, 4.5 million ... the first time, the results of the decay and fossilisation ... possibly a baleen whale from the Mysticeti group. , This ... of a whale from the Lower Pliocene (five million years ... the first time that the results of the processes of ...
(Date:12/15/2009)... standard laboratory model organism, but there are currently ... blood and blood-forming tissues in this species. ... laboratory resources from Cold Spring Harbor Laboratory Press ... features step-by-step protocols for the preparation, enumeration, and ... other hematopoietic tissues in the mouse. The ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3New source of classical techniques for blood-based studies in the laboratory mouse 2IPC The Hospitalist Company Inc to Report Second Quarter 2009 Results 52237 1IPC The Hospitalist Company Inc to Report Second Quarter 2009 Results 52237 2BioNeutrals Ygiene 28TM 29 Hospital Grade Achieves a 100 25 Total Kill 28Pass 29 Against the Life Threatening Clostridium Difficile 28C diff 29 Spor 13123 1BioNeutrals Ygiene 28TM 29 Hospital Grade Achieves a 100 25 Total Kill 28Pass 29 Against the Life Threatening Clostridium Difficile 28C diff 29 Spor 13123 2BioNeutrals Ygiene 28TM 29 Hospital Grade Achieves a 100 25 Total Kill 28Pass 29 Against the Life Threatening Clostridium Difficile 28C diff 29 Spor 13123 3My InnerView and UW Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 52230 1My InnerView and UW Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 52230 2My InnerView and UW Eau Claire Announce New Online Health Management Certificate Program for Senior Care Professionals 52230 3
... The asteroid presumed to have wiped out the dinosaurs ... in the Earth,s crust liquefied, rocketed skyward, and formed ... from the U.S., U.K., Italy, and New Zealand in ... geologists as carbon cenospheres, cannot be formed through the ...
... role to play in the fate of potentially dangerous depleted ... to a new report in the May 6th issue of ... researchers found evidence that fungi can lock depleted uranium into ... its way into plants, animals, or the water supply. , ...
... currently a grave concern for governments and health organisations around ... bird flu strains, such as H5N1, to develop the ability ... the spread of the virus are badly needed. Now one ... the machinery of infected cells has been laid bare by ...
Other Biology News:65-million-year-old asteroid impact triggered a global hail of carbon beads 265-million-year-old asteroid impact triggered a global hail of carbon beads 3Fungi have a hand in depleted uranium's environmental fate 2Getting wise to the influenza virus' tricks 2
...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... mixed TAMRA isomers are predominantly used for ... preferred for labeling peptides and nucleotides because ... that is often required in the conjugation ... 6-TAMRA for labeling peptides and proteins. 6-TAMRA ...
Biology Products: